10X Genomics ( (TXG) ) has released its Q2 earnings. Here is a breakdown of the information 10X Genomics presented to its investors.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
10x Genomics, Inc. is a life science technology company specializing in single cell and spatial biology solutions, providing integrated research tools to advance human health and biological understanding.
In its second quarter of 2025 financial report, 10x Genomics announced a revenue of $172.9 million, with a notable contribution from a patent litigation settlement. The company also highlighted strategic moves such as the acquisition of Scale Biosciences and a partnership with the Genome Institute of Singapore to enhance its technological capabilities and market reach.
Key financial metrics revealed a gross margin increase to 72% and a significant reduction in operating expenses by 35%, leading to an operating income of $30.1 million compared to a loss in the previous year. The net income stood at $34.5 million, marking a positive turnaround from the prior year’s loss. The company also reported a healthy cash position with $447.3 million in cash and marketable securities.
Looking ahead, 10x Genomics projects third-quarter revenue between $140 million and $144 million, reflecting adjustments due to anticipated tariff changes. The company remains focused on disciplined execution and leveraging its technological strengths to capitalize on long-term opportunities in the life sciences sector.